Literature DB >> 8477196

Pure red cell aplasia following ABO mismatched marrow transplantation for chronic lymphocytic leukemia: response to antithymocyte globulin.

P J Bierman1, P Warkentin, M R Hutchins, L W Klassen.   

Abstract

Pure red cell aplasia was observed in a 28 year old woman following a major ABO mismatched allogeneic bone marrow transplant for chronic lymphocytic leukemia. No evidence of red blood cell production was observed for more than one year following transplant despite the absence of high isohemagglutinin titers. Treatment with antithymocyte globulin resulted in prompt restoration of reticulocytosis. Therapy with antithymocyte globulin should be considered in these instances when red cell aplasia follows mismatched allogeneic marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8477196     DOI: 10.3109/10428199309148522

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  Use of anti-thymocyte globulin (ATG) for the treatment of pure red cell aplasia and immune-mediated cytopenias after allogeneic hematopoietic cell transplantation: a case series.

Authors:  Alexandra Gomez-Arteaga; Michael Scordo; Roni Tamari; Josel D Ruiz; Ann A Jakubowski; Esperanza B Papadopoulos; Sergio A Giralt; Miguel-Angel Perales; Hugo R Castro-Malaspina; Craig S Sauter; Parastoo B Dahi
Journal:  Bone Marrow Transplant       Date:  2020-05-18       Impact factor: 5.483

Review 2.  Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Authors:  Javier Marco-Ayala; Inés Gómez-Seguí; Guillermo Sanz; Pilar Solves
Journal:  Bone Marrow Transplant       Date:  2020-11-14       Impact factor: 5.483

3.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.

Authors:  Georg Stussi; Jörg Halter; Eveline Bucheli; Piero V Valli; Lutz Seebach; Jürg Gmür; Alois Gratwohl; Urs Schanz; Jakob R Passweg; Jörg D Seebach
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

4.  Prevalence of Pure Red Cell Aplasia Following Major ABO-Incompatible Hematopoietic Stem Cell Transplantation.

Authors:  Panpan Zhu; Yibo Wu; Dawei Cui; Jimin Shi; Jian Yu; Yanmin Zhao; Xiaoyu Lai; Lizhen Liu; Jue Xie; He Huang; Yi Luo
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.